<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898466</url>
  </required_header>
  <id_info>
    <org_study_id>Bio ID 366</org_study_id>
    <nct_id>NCT03898466</nct_id>
  </id_info>
  <brief_title>Effect of Fluticasone Furoate on Methacholine Challenge</brief_title>
  <official_title>The Effect of Once-daily Fluticasone Furoate on Methacholine-induced Bronchoconstriction in Mild Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the effect of inhaled fluticasone furoate on airway responsiveness
      to methacholine in mild asthmatics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methacholine provocation dose causing a 20% fall in FEV1 (PD20)</measure>
    <time_frame>24 hours post dose, 72 hours post dose and 168 hours post dose</time_frame>
    <description>Change from baseline in airway response to inhaled methacholine following daily dosing with fluticasone furoate or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional exhaled nitric oxide (FeNO)</measure>
    <time_frame>168 hours</time_frame>
    <description>Change from baseline on levels of fractional exhaled nitric oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum eosinophils</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessment of induced sputum differential cell counts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone Furoate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.
The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.
The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone furoate</intervention_name>
    <description>Inhaled corticosteroid</description>
    <arm_group_label>Fluticasone Furoate</arm_group_label>
    <other_name>Arnuity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Placebo inhaler</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  forced expiratory volume in one second (FEV1) greater than or equal to 65% predicted

          -  methacholine PD20 less than or equal to 400mcg

          -  no allergen exposure (if atopic) or respiratory infection for at least 4 weeks prior
             to study start

        Exclusion Criteria:

          -  regular use of inhaled corticosteroid within 4 weeks of study start

          -  poorly controlled asthma

          -  current smoker or ex smoker with greater than 10 pack year history

          -  pregnancy or breast-feeding

          -  health concern/condition that would preclude participation for safety reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

